Our community has lost another pioneer and lifelong contributor to BMT. ASTCT sends its deepest condolences to the family, friends, colleagues & countless others impacted by Dr. Miller. Colleague McGlave says, "He was always excellent in a low-key way.” https://t.co/CK1aZ59T5P
Targeting the Microbiome to Treat Malnutrition. An important study conducted in Bangladesh. Microbiome-friendly formulation of chickpea, soy, peanut, and banana. https://t.co/exmICvNWLK Full text Science corrected proof https://t.co/9OerPjJQeQ @MRegueiroMD@morowitzmj@askbmtdoc
https://t.co/XQOtxaiIXP FDA approves ruxolitinib for steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. The recommended starting dose of ruxolitinib for GVHD is 5 mg given orally twice daily https://t.co/UimxCJ3243 @aGVHD@gvhd_hub @BldCancerDoc
I am humbled and honored to be selected for the #ASPHO Young Investigator Award. Look forward to presenting our research on the genetics of fetal hemoglobin regulation at @ASPHO_hq annual meeting @StJudeResearch@StJude https://t.co/IX2Gj6aAjt
How to improve the diversity of your microbiome?
1, 2 & 3: Avoid unnecessary antibiotics. Probiotics are killed by stomach acid, and no one adheres to any diet.
Hear from our new President on why we're changing our name and what's to come! Full video can be accessed on our Facebook page: https://t.co/ItE4Emr6Yb
Shout out to the one-and-only, the always amazing, the brilliant and dynamic: @BldCancerDoc 👉👉👉Officially now Beginning his administration as the President of the now: American Society for Transplantation and Cellular Therapy, ASTCT {formerly @ASBMT} #TCTM19#bmtsm#ImmunoOnc
So proud of @BldCancerDoc, a close friend and a born leader, for being elected as the President of ASBMT, now christened ASTCT (American Society of Transplantation and Cell Therapy)
#TCTM19 Baricitinib-induces blockade of IFNGR and IL-6R, prevents and treats GVHD and has GVL effects in murine model. @BldCancerDoc @ASBMT@CIBMTR @NMDP @dharmabmt @satya_yadav